HUP0500443A2 - Himbacin analógok mint trombin receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Himbacin analógok mint trombin receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0500443A2 HUP0500443A2 HU0500443A HUP0500443A HUP0500443A2 HU P0500443 A2 HUP0500443 A2 HU P0500443A2 HU 0500443 A HU0500443 A HU 0500443A HU P0500443 A HUP0500443 A HU P0500443A HU P0500443 A2 HUP0500443 A2 HU P0500443A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- alkenyl
- alkyl
- chlorophenyl
- Prior art date
Links
- FMPNFDSPHNUFOS-LPJDIUFZSA-N himbacine Chemical class C(/[C@@H]1[C@H]2CCCC[C@@H]2C[C@@H]2C(=O)O[C@H]([C@H]12)C)=C\[C@H]1CCC[C@H](C)N1C FMPNFDSPHNUFOS-LPJDIUFZSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
- -1 carboxy, sulfinyl Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 229910006069 SO3H Chemical group 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
A találmány tárgyát az általános képletű heterociklikusszubsztituenseket hordozó háromgyűrűs vegyületek - ahol n1 és n2egymástól függetlenül 0-2 lehet; Het adott esetben szubsztituált egy-,két- vagy háromgyűrűs heteroaromás csoport; B alkil- vagy adottesetben szubsztituált alkenilcsoport; R22 -COR23 általános képletűcsoport vagy egy karboxi-, szulfinil-, szulfonil-, szulfonamid- vagyaminosavszármazék; R23 halogénezett alkil-, alkenil-, halogénezettalkenil-, alkinil-, adott esetben szubsztituált cikloalkil-,cikloalkil-alkil-, aril-, aril-alkil-, heteroaril-, heterocikloalkil-vagy -COOH és/vagy SO3H csoporttal szubsztituált alkilcsoport; R1, R2,R3, R9, Rl0 és Rll a szerves kémiában szokásos , adott esetbenösszetett szubsztituensek és ezeket tartalmazó, trombózissal,arteroszklerózissal, restenózissal, magas vérnyomással, szívtájiszorító fájdalommal, aritmiával, szívelégtelenséggel és rákkalösszefüggő betegségek kezelésére szolgáló gyógyszerkészítményekképezik. A találmány tárgya továbbá az általános képletű vegyületekis, ahol W jelentése 3-trifluormetilfenil-, 3-fluorfenil-, 2,3-difluorfenil-, 3- klórfenil-, 2-klórfenil- vagy 2,3-diklórfenilcsoport, Z jelentése oxigénatom, kénatom, SO<>-csoport,SO2-csoport, NH-csoport vagy metilcsoporttal, alkilkarbonilcsoporttal,benzolcsoporttal vagy aminokarbonilcsoporttal szubsztituáltnitrogénatom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33035901P | 2001-10-18 | 2001-10-18 | |
| PCT/US2002/032936 WO2003033501A1 (en) | 2001-10-18 | 2002-10-16 | Himbacine analogues as thrombin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0500443A2 true HUP0500443A2 (hu) | 2005-08-29 |
| HUP0500443A3 HUP0500443A3 (en) | 2009-12-28 |
Family
ID=23289411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0500443A HUP0500443A3 (en) | 2001-10-18 | 2002-10-16 | Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7037920B2 (hu) |
| EP (1) | EP1436298B1 (hu) |
| JP (2) | JP4307260B2 (hu) |
| KR (1) | KR100960170B1 (hu) |
| CN (1) | CN100369917C (hu) |
| AR (1) | AR036832A1 (hu) |
| AT (1) | ATE525378T1 (hu) |
| AU (1) | AU2002335031C1 (hu) |
| BR (1) | BR0213967A (hu) |
| CA (1) | CA2463628A1 (hu) |
| CO (1) | CO5570668A2 (hu) |
| EC (1) | ECSP045064A (hu) |
| HU (1) | HUP0500443A3 (hu) |
| IL (1) | IL160918A0 (hu) |
| MX (1) | MXPA04003610A (hu) |
| MY (1) | MY139335A (hu) |
| NO (1) | NO329349B1 (hu) |
| NZ (1) | NZ531869A (hu) |
| PE (1) | PE20030808A1 (hu) |
| PL (1) | PL371948A1 (hu) |
| RU (1) | RU2319704C9 (hu) |
| WO (1) | WO2003033501A1 (hu) |
| ZA (1) | ZA200402849B (hu) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| ATE378330T1 (de) | 2002-04-16 | 2007-11-15 | Schering Corp | Trizyklische thrombin rezeptor antagonisten |
| WO2005007868A2 (en) * | 2003-07-08 | 2005-01-27 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of adp antagonists |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| ATE406366T1 (de) * | 2004-05-28 | 2008-09-15 | Schering Corp | Gehinderte himbacinanaloga als thrombinrezeptorantagonisten |
| EP1778652A2 (en) * | 2004-08-20 | 2007-05-02 | EntreMed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| CA2582353A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006041872A2 (en) * | 2004-10-08 | 2006-04-20 | Schering Corporation | Thrombin receptor antagonists |
| PL2206697T3 (pl) | 2005-01-14 | 2012-03-30 | Merck Sharp & Dohme | Egzo- oraz diastereoselektywna synteza analogów himbacyny |
| US7772276B2 (en) * | 2005-01-14 | 2010-08-10 | Schering Corporation | Exo-selective synthesis of himbacine analogs |
| WO2006076564A1 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | Synthesis of himbacine analogs |
| KR20070116066A (ko) * | 2005-03-31 | 2007-12-06 | 쉐링 코포레이션 | 스피로사이클릭 트롬빈 수용체 길항제 |
| US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| CN101384590A (zh) * | 2005-12-22 | 2009-03-11 | 先灵公司 | 作为凝血酶受体拮抗剂的唑并异喹啉 |
| EP1971336A2 (en) * | 2005-12-22 | 2008-09-24 | Shering Corporation | Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery |
| KR20080104352A (ko) * | 2006-03-29 | 2008-12-02 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서 유용한 모노사이클릭 및 비사이클릭 힘바신 유도체 |
| EP2266976B1 (en) | 2006-04-13 | 2013-07-31 | Merck Sharp & Dohme Corp. | Fused ring thrombin receptor antagonists |
| AR061664A1 (es) * | 2006-06-29 | 2008-09-10 | Schering Corp | Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas. |
| AR061727A1 (es) | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| WO2008060372A2 (en) * | 2006-10-04 | 2008-05-22 | Schering Corporation | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| US8153664B2 (en) * | 2006-10-04 | 2012-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| WO2008079260A2 (en) * | 2006-12-22 | 2008-07-03 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| JP2010522169A (ja) * | 2007-03-23 | 2010-07-01 | シェーリング コーポレイション | トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減 |
| KR20100017576A (ko) * | 2007-05-03 | 2010-02-16 | 아큐메트릭스, 인크. | 트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법 |
| MY152040A (en) | 2008-02-05 | 2014-08-15 | Sanofi Aventis | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| EP2300435A2 (en) | 2008-05-19 | 2011-03-30 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| WO2010141525A1 (en) | 2009-06-04 | 2010-12-09 | Schering Corporation | Active metabolite of a thrombin receptor antagonist |
| EP2440191A2 (en) | 2009-06-08 | 2012-04-18 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| US9340530B2 (en) | 2012-03-06 | 2016-05-17 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |
| EP3035928B1 (en) | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| WO2015026693A1 (en) | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| EP3035930A4 (en) | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| CN104610330A (zh) * | 2015-02-25 | 2015-05-13 | 成都安斯利生物医药有限公司 | 一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法 |
| JP2023534704A (ja) | 2020-07-22 | 2023-08-10 | ヤンセン ファーマシューティカ エヌ．ベー． | 第ｘｉａ因子阻害剤として有用な化合物 |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716952A (en) | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| JP2000229961A (ja) * | 1998-12-11 | 2000-08-22 | Sagami Chem Res Center | ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法 |
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| DE19801636A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte bicyclische Lactone |
| CA2410177C (en) | 2000-06-15 | 2010-05-11 | Schering Corporation | Thrombin receptor antagonists |
-
2002
- 2002-10-16 MX MXPA04003610A patent/MXPA04003610A/es active IP Right Grant
- 2002-10-16 MY MYPI20023859A patent/MY139335A/en unknown
- 2002-10-16 KR KR1020047005435A patent/KR100960170B1/ko not_active IP Right Cessation
- 2002-10-16 CA CA002463628A patent/CA2463628A1/en not_active Abandoned
- 2002-10-16 PE PE2002001022A patent/PE20030808A1/es not_active Application Discontinuation
- 2002-10-16 US US10/271,715 patent/US7037920B2/en not_active Expired - Fee Related
- 2002-10-16 AR ARP020103876A patent/AR036832A1/es unknown
- 2002-10-16 EP EP02801732A patent/EP1436298B1/en not_active Expired - Lifetime
- 2002-10-16 AU AU2002335031A patent/AU2002335031C1/en not_active Ceased
- 2002-10-16 JP JP2003536240A patent/JP4307260B2/ja not_active Expired - Fee Related
- 2002-10-16 WO PCT/US2002/032936 patent/WO2003033501A1/en active IP Right Grant
- 2002-10-16 BR BR0213967-7A patent/BR0213967A/pt not_active IP Right Cessation
- 2002-10-16 AT AT02801732T patent/ATE525378T1/de not_active IP Right Cessation
- 2002-10-16 NZ NZ531869A patent/NZ531869A/en not_active IP Right Cessation
- 2002-10-16 IL IL16091802A patent/IL160918A0/xx not_active IP Right Cessation
- 2002-10-16 HU HU0500443A patent/HUP0500443A3/hu unknown
- 2002-10-16 RU RU2004115114/04A patent/RU2319704C9/ru not_active IP Right Cessation
- 2002-10-16 CN CNB028206665A patent/CN100369917C/zh not_active Expired - Fee Related
- 2002-10-16 PL PL02371948A patent/PL371948A1/xx not_active Application Discontinuation
-
2004
- 2004-04-15 EC EC2004005064A patent/ECSP045064A/es unknown
- 2004-04-15 ZA ZA200402849A patent/ZA200402849B/xx unknown
- 2004-04-16 CO CO04034781A patent/CO5570668A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042021A patent/NO329349B1/no not_active IP Right Cessation
-
2005
- 2005-12-19 US US11/311,083 patent/US20060106050A1/en not_active Abandoned
-
2008
- 2008-09-17 JP JP2008238716A patent/JP2009029820A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0500443A2 (hu) | Himbacin analógok mint trombin receptor antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények | |
| RU2378263C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| DE602007008550D1 (de) | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung | |
| NO20023218D0 (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| NO20023097L (no) | Heterocykliske forbindelser med sulfonamidgrupper | |
| TR200003634T2 (tr) | Benzo(b)tiyepin-1,1-dioksid türevleri, üretim yöntemi, bunları içeren ilaçlar | |
| DE60140456D1 (de) | Aza heterocyclische derivate und ihre therapeutische verwendung | |
| NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
| ATE556058T1 (de) | 1-(2h)-isochinolonderivat | |
| HUP0200310A2 (hu) | Triciklikus pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására és az új vegyületek | |
| WO2008005914A3 (en) | Novel glucokinase activators and methods of using same | |
| HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
| WO2008078196A3 (en) | Substituted heteroaryl pyridopyrimidone derivatives | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| NO20050666L (no) | 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer | |
| TW200740806A (en) | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| HUP0000189A2 (hu) | Biciklusos aril-karboxamid-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk terápiás célokra | |
| NO20063865L (no) | Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter | |
| HUP0300994A2 (hu) | Pirrolidinszármazékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
| WO2003082861A3 (en) | Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases | |
| DE3882895T2 (de) | Imid-Derivate, ihre Herstellung und Verwendung. | |
| AP9701079A0 (en) | Sulfonamides. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |